In this video, Chief Development Officer Yalia Jayalakshmi, Ph.D. explains why she joined Imagion Biosystems, the urgency of the company’s mission, and the challenges ahead.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)